BGJ398

PreclinicalSmall molecule

Novartis

BGJ398 is one of 56 small molecule programs targeting Urothelial Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urothelial CarcinomaActive, not recruiting

Urothelial CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Urothelial Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Gemzar

Johnson & Johnson

Phase 3

24 3

Tecentriq

Roche

Phase 3

19 4

Opdivo

Bristol-Myers Squibb

Phase 3

12 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

20 6

Taxol

Teva

Phase 3

4 7

Paraplatin

AAvyxa

Phase 3

12 8

Taxotere

AAvyxa

Phase 3

6 9

Tuoyi

CCoherus Oncology, Inc.

Phase 3

4 10

Alimta

SShawn Eagle

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cholangiocarcinoma2 trials

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Terminated·QQED Therapeutics, a BridgeBio company·Phase 2·NCT02150967·143 enrolled

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Terminated·QQED Therapeutics, a BridgeBio company·Phase 3·NCT03773302·48 enrolled

Solid Tumors1 trial

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Completed· Novartis logo

Novartis·Phase 1·NCT01928459·62 enrolled

Other Solid Tumors1 trial

Ph Ib/BGJ398/Cervix and Other Solid Tumors

Withdrawn·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT02312804

Advanced Solid Malignancies1 trial

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Completed· Novartis logo

Novartis·Phase 1·NCT01004224·208 enrolled

Recurrent Head and Neck Cancer1 trial

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Terminated·UUniversity of Chicago·Phase 2·NCT02706691·1 enrolled

7 more indications

Tumors1 trial

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Terminated· Novartis logo

Novartis·Phase 2·NCT02160041·84 enrolled

Melanoma1 trial

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Completed· Pfizer logo

Pfizer·Phase 2·NCT02159066·158 enrolled

Oral1 trial

A Phase I Study of Oral BGJ398 in Asian Patients

Completed· Novartis logo

Novartis·Phase 1·NCT01697605·9 enrolled

Gastrointestinal Stromal Tumor1 trial

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02257541·16 enrolled

Tumor-Induced Osteomalacia1 trial

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

Terminated·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT03510455·4 enrolled

Recurrent1 trial

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Completed· Novartis logo

Novartis·Phase 2·NCT01975701·26 enrolled

Bladder Cancer1 trial

Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Completed·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT02657486·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for BGJ398. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BGJ398 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BGJ398. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Novartis

BGJ398

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cholangiocarcinoma2 trials

Solid Tumors1 trial

Other Solid Tumors1 trial

Advanced Solid Malignancies1 trial

Recurrent Head and Neck Cancer1 trial

Tumors1 trial

Melanoma1 trial

Oral1 trial

Gastrointestinal Stromal Tumor1 trial

Tumor-Induced Osteomalacia1 trial

Recurrent1 trial

Bladder Cancer1 trial

References

Drug Info

Quick Facts

Related News